Treatment with any of the following therapies: \r\n* Radiation therapy, surgery or tumor embolization within  days prior to the first dose of pazopanib hydrochloride OR\r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within  days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib\r\n* Patients who require chronic use of strong cytochrome P A (CYPA) inhibitors or inducers including but not limited to grapefruit juice
Treatment with any of the following anti-cancer therapies =<  days prior to registration:\r\n* Radiation therapy\r\n* Surgery or tumor embolization\r\n* Chemotherapy, immunotherapy\r\n* Biologic therapy\r\n* Investigational therapy\r\n* Hormonal therapy
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib, other agents being investigated in combination with regorafenib)
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib, other agents being investigated in combination with regorafenib)
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment; the washout period between radiation therapy or tumor embolization is two weeks; given the refractory nature of the study population, the washout period between study treatment and prior chemotherapy or biological therapy, will be three weeks prior to use of regorafenib
Currently receiving other anti-cancer therapy (chemotherapy, radiation therapy, immuno- therapy, biologic therapy, hormonal therapy, surgery, and/or tumour embolization)
Currently receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, and surgery and/or tumor embolization) or any investigational drug within  days of cycle /day ,  days of cycle /day  for limited palliative radiation, and/or five half-live of an oral therapy\r\n* Corticosteroid therapy started at least  days prior to initiation of treatment (prednisone =<  mg daily or equivalent) is allowed as clinically warranted); topical or inhaled corticosteroids are permitted
Patients who are receiving concurrent non-protocol anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, or tumor embolization) are to be excluded
Treatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, surgery, or tumor embolization within  days prior to the first dose of pazopanib OR\r\n* Chemotherapy, immunotherapy, investigational therapy, or hormonal therapy within  days prior to the first dose of pazopanib
Treatment with any of the following anti-cancer therapies: radiation therapy, surgery or tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy =<  days prior to registration
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment regorafenib; however, the palliative radiation therapy (XRT) to non-targeted lesions is allowed
Concurrent anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, tumor embolization, or biologic therapy including pertuzumab, but except IV trastuzumab or hormonal therapy, if patient is already being treated with either of the two agents)
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib, other agents being investigated in combination with regorafenib).
Concurrent anti-cancer therapy (chemotherapy, definitive radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment; concurrent therapy with bisphosphonates or denosumab for bone metastases is allowed; palliative radiation to non-target lesions is also allowed
Concurrent anti-cancer therapy =<  weeks from registration (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)
Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) within  weeks of cycle /day  with the following exceptions:\r\n* Limited palliative radiation is allowed if completed >=  weeks of cycle  day  (CD)\r\n* Corticosteroid therapy (prednisone or equivalent =<  mg daily) is allowed as clinically warranted as long as the dose is stabilized at least for  days prior to initial dosing; topical or inhaled corticosteroids are permitted\r\n* Patients currently taking ibrutinib do not need to undergo a washout period
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than the protocol based treatment; LHRH agonist or antagonist therapy and bisphosphonates or denosumab are allowed
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment
Concurrent anti-cancer therapy (chemotherapy, definitive radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment; concurrent therapy with bisphosphonates or denosumab for bone metastases is allowed; palliative radiation to non-target lesions is also allowed
Treatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, surgery or tumor embolization within  days prior to the first dose of study treatment
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than sorafenib
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization)
Treatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, chemotherapy, immunotherapy, biologic therapy, investigational therapy\r\n* Surgery or tumor embolization within  days prior to the first dose of pazopanib OR\r\n* Hormonal therapy within  days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
Patients currently receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization)
Concurrent systemic and local anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than sorafenib
Patient must not have had radiation therapy, minor surgery, or tumor embolization with  days prior to the first dose of pazopanib
Patients must be at least  days from last radiation therapy dose, surgery, or tumor embolization prior to the first dose of pazopanib/PCI-
Treatment with any of the following anti-cancer therapies: \r\n* Radiation therapy, surgery or tumor embolization within  days prior to the first dose of pazopanib OR \r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within  days or five half-lives of a drug (whichever is longer) prior to the first dose of pazopanib
Prior treatment with any of the following anti-cancer therapies for treatment of their renal cell carcinoma (RCC):\r\n* Radiation therapy, surgery or tumor embolization\r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy
Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) within  days of starting study treatment; palliative radiation is allowed
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) within  weeks of starting study treatment
Concurrent anticancer therapy (eg, chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, investigational therapy, or tumor embolization).
Radiation therapy, minor surgery, tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within  days prior to the protocol-mandated -week drug holiday.
Concurrent anti-cancer therapy (chemotherapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than study treatment (regorafenib)
Concurrent anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy [other than that specified by the protocol], surgery, immunotherapy, biologic therapy including lapatinib, bevacizumab, tyrosine kinase inhibitors other than sorafenib or tumor embolization); trastuzumab will be allowed to continue for human epidermal growth factor receptor  positive (HER+) patients
Radiation therapy, surgery (except major surgery), tumor embolization, chemotherapy, immunotherapy, biologic therapy, investigational therapy, or hormonal therapy within  days or five half-lives of a drug (whichever is longer) prior to the first dose of study drug.
Treatment with any other anti-cancer therapies (e.g. other radiation, surgery or tumor embolization) within the last  days prior to first dose of study drug; or chemotherapy, immunotherapy, biologic therapy, investigational or hormonal therapy within -days (or  half-lives of a drug whichever is longer) prior to the first dose of the study drug pazopanib
Anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) within  weeks prior to entering the study (signing of consent form) or those who have not recovered from adverse events due to agents administered more than  weeks earlier; patients on hormonal or bisphosphonate treatment for non-cancer related conditions are eligible
Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than regorafenib
Patients receiving cancer therapy (i.e., chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization) within  weeks of cycle /day  with the following exceptions:\r\n* Corticosteroid therapy (prednisone or equivalent =<  mg daily) is allowed as clinically warranted as long as the dose is stabilized at least for  days prior to initial dosing; topical or inhaled corticosteroids are permitted\r\n* Patients who may experience clinical deterioration may start therapy after a shorter washout period with prior approval by the principal investigator (PI)
Concurrent anti-cancer therapy (chemotherapy, hormonal therapy, radiation therapy, surgery, immunotherapy, biologic therapy, or tumor embolization) other than sorafenib, and protocol-specified whole-brain radiotherapy
Must not have treatment with any of the following anti-cancer therapies:\r\n* Radiation therapy, surgery or tumor embolization within  days prior to the first dose of pazopanib OR\r\n* Chemotherapy, immunotherapy, biologic therapy, investigational therapy or hormonal therapy within  days prior to the first dose of pazopanib\r\n* Treatment with prior sorafenib, sunitinib, temsirolimus or everolimus is allowed but must be discontinued at least  days prior to beginning pazopanib
Patients that have previously received an ALK TKI or PD-/PD-L therapy, and patients currently receiving cancer therapy (i.e., other targeted therapies, chemotherapy, radiation therapy, immunotherapy, biologic therapy, hormonal therapy, surgery and/or tumor embolization).
